Biotech Investor Alex Karnal: GLP-1 Drugs Signal ‘Trillion-Dollar Revolution’ in Public Health

1 hour ago 3

Ian Cooper

Wed, April 22, 2026 astatine 11:24 AM CDT 5 min read

Alex Karnal, co-founder and CIO of Braidwell, a beingness sciences concern firm, spent 20 years gathering and backing biotech companies earlier declaring connected the Invest Like the Best podcast that "2025 was astir apt the azygous astir breathtaking twelvemonth successful my full journey." The catalyst: GLP-1 medicines. His assertion deserves scrutiny due to the fact that the concern and idiosyncratic wellness implications are substantial.

Karnal's statement has 2 parts. First, the commercialized case: "This is simply a people of medicines that volition easy beryllium successful excess of $100 cardinal a twelvemonth successful revenue." Second, the structural case: GLP-1 adoption is "the archetypal commercialized impervious that we are acceptable for what I deliberation we're gonna look backmost connected successful clip arsenic a once-in-a-lifetime trillion-dollar gyration successful each of nationalist health." He frames this not arsenic a pharmaceutical occurrence communicative but arsenic a behavioral shift, with consumers "voting with their feet" to determination from reactive illness attraction to proactive wellness protection.

The structural lawsuit is harder to price: GLP-1 adoption arsenic a behavioral displacement toward proactive wellness is simply a compelling framework, but the timeline and argumentation situation stay genuinely uncertain.

Eli Lilly (NYSE: LLY) generated combined GLP-1 cause income of $36.5 cardinal successful 2025, comprising astir 56% of the company's full revenues. Its banal has gained 11% implicit the past twelvemonth and an bonzer 407% implicit 5 years. Peer-reviewed probe published successful 2025 confirmed that GLP-1 medicines "improve outcomes successful radical with cardiovascular, kidney, liver, arthritis, and slumber apnea disorders" done anti-inflammatory and metabolic pathways, with immoderate benefits occurring independently of value nonaccomplishment itself.

GLP-1 drugs were designed for humor sweetener power successful Type 2 diabetics, but their benefits successful cardiovascular disease, kidney disease, and metabolic liver illness emerged from trials alternatively than intent, which is portion of what makes the level truthful unusual.

Karnal's $100 cardinal yearly gross level is credible, but the way determination is messier than the podcast framing suggests. Analysts astatine Jefferies revised down their forecast for the weight-loss marketplace to a highest of $80 cardinal from an earlier estimation of implicit $100 cardinal by the aboriginal 2030s. Goldman Sachs pegged planetary obesity cause income astatine $105 cardinal by 2030, down from earlier forecasts of $130 billion, citing steeper terms erosion. The $150 cardinal fig that Wall Street erstwhile treated arsenic a level has shifted to a 2035 people for immoderate analysts.

Read Entire Article